0001104659-21-041312.txt : 20210325 0001104659-21-041312.hdr.sgml : 20210325 20210325110508 ACCESSION NUMBER: 0001104659-21-041312 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210325 DATE AS OF CHANGE: 20210325 EFFECTIVENESS DATE: 20210325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lennham Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001853301 IRS NUMBER: 833016066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-393490 FILM NUMBER: 21770899 BUSINESS ADDRESS: STREET 1: 53 MAIN STREET STREET 2: SUITE 206 CITY: CONCORD STATE: MA ZIP: 01742 BUSINESS PHONE: 6173887171 MAIL ADDRESS: STREET 1: 53 MAIN STREET STREET 2: SUITE 206 CITY: CONCORD STATE: MA ZIP: 01742 D 1 primary_doc.xml X0708 D LIVE 0001853301 Lennham Pharmaceuticals, Inc. 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 617 388-7171 DELAWARE None None Corporation true 2019 Bradford C. Sippy 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Director Benjamin D. Enerson 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Corey MacGregor 53 Main Street Suite 206 Concord MA MASSACHUSETTS 01742 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2019-10-19 false true false 50000 2325000 2325000 0 Offering and sales amounts consist of convertible note investments with an aggregate principal amount of $2,325,000. false 19 0 0 0 false Lennham Pharmaceuticals, Inc. /s/ Bradford C. Sippy Bradford C. Sippy CEO 2021-03-24